Source: San Jose Mercury News
With a new gene technology known as CRISPR-Cas9, Stanford scientists are developing ways to perform “…genomic surgery with a precision, efficiency and affordability once thought unimaginable,” reports the San Jose Mercury News.
Stanford’s research, led by Dr. Matthew Porteus at its School of Medicine, is just one lab involved in a larger movement to unlock the benefits of CRISPR-Cas9, including curing genetic diseases like sickle cell anemia and muscular dystrophy. Dr. Porteus’ team hopes to begin human trials in 2018 to target blood and immune system diseases.
Other labs across the country, both university-affiliated and independent, are racing to develop treatments using this new technique. New biotech companies are working to raise the money necessary to bring these therapies to the market.
Read full story at: San Jose Mercury News